Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Vibha Ravi

Latest From Vibha Ravi

Biocon Biologics And Serum Institute Join Forces

Serum to hold 15% in Biocon arm Biocon Biologics as part of a broad alliance that expects to leverage the partners' strengths and resources in vaccines and biologics. Pursuing opportunities based on the hot mRNA technology platform appears firmly on the table.

Deals India

Biocon-Serum Combine Forces, mRNA Opportunities On Radar

Serum to hold 15% in Biocon arm Biocon Biologics as part of a broad alliance that expects to leverage the partners' strengths and resources in vaccines and biologics. Pursuing opportunities based on the hot mRNA technology platform appears firmly on the table.

India Vaccines

TB Alliance-Lupin Deal To Improve Pretomanid Access But India Unlikely To Benefit For Now

While Viatris says it has sufficient capacity to meet current and future demand for tuberculosis drug pretomanid, TB Alliance has signed a non-exclusive license with Lupin. This is the second tie-up with an Indian manufacturer but the local restricted use approval means countries other than India are likely to benefit for now.

Commercial Manufacturing

After Zydus' Historic COVID-19 DNA Vaccine Approval, Inovio To Enter Phase III

Soon after Zydus Cadila won a historic accelerated approval in India for the world’s first plasmid DNA vaccine for human use, in this case against COVID-19, Inovio’s candidate is set to move to Phase III in Brazil. But will the new technology find wide acceptance?

Approvals Coronavirus COVID-19

Asia Deal Watch: Innovent And Bolt Collaborate On Immune-Stimulating Antibody Conjugates

Partners will share development and commercial rights to up to three ISAC products for cancer. Wockhardt licenses China rights for novel antibiotic to Jiangsu Jemincare.

Deal Watch Business Strategies

Indian Biotech In mRNA Push As COVID-19 Vaccine Moves To Phase II

Gennova Biopharma’s mRNA ambitions are taking wing as its HDT Bio-partnered self-amplifying vaccine moves to Phase II. Notably, the company will have to prove superiority to AstraZeneca/Serum Institute’s Covishield in what appears to be the first comparative study for a COVID-19 vaccine candidate in India, Scrip learns.

Research & Development Coronavirus COVID-19
See All
UsernamePublicRestriction

Register